Boardroom Alpha
Start trial
10-K primary document
IRON · Annual Report (Form 10-K) · Filed February 26, 2026

Disc Medicine Inc — 10-K exhibit

iron-ex23_1.htm
Disc Medicine Inc on Boardroom Alpha
EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-3 No. 333-269270) of Disc Medicine, Inc.,
(2)
Registration Statement (Form S-3 No. 333-281359) of Disc Medicine, Inc.,
(3)
Registration Statement (Form S-8 No. 333-285312) pertaining to the Amended and Restated 2021 Stock Option and Incentive Plan, Amended and Restated 2021 Employee Stock Purchase Plan, the Stock Option Inducement Awards, and the Restricted Stock Unit Inducement Awards of Disc Medicine, Inc.,
(4)
Registration Statement (Form S-8 No. 333-278129) pertaining to the Amended and Restated 2021 Stock Option and Incentive Plan, Amended and Restated 2021 Employee Stock Purchase Plan, the Stock Option Inducement Awards, and the Restricted Stock Unit Inducement Awards of Disc Medicine, Inc.,
(5)
Registration Statement (Form S-8 No. 333-269271) pertaining to the 2017 Stock Option and Grant Plan, Amended and Restated 2021 Stock Option and Incentive Plan, and Amended and Restated 2021 Employee Stock Purchase Plan of Disc Medicine, Inc.,
(6)
Registration Statement (Form S-8 No. 333-263410) pertaining to the 2021 Stock Option and Incentive Plan of Gemini Therapeutics, Inc.,
(7)
Registration Statement (Form S-8 No. 333-255194) pertaining to the 2021 Stock Option and Incentive Plan and the 2021 Inducement Plan of Gemini Therapeutics, Inc., and
(8)
Registration Statement (Form S-8 No. 333-260243) pertaining to the 2021 Employee Stock Purchase Plan of Gemini Therapeutics, Inc.;

of our reports dated February 26, 2026, with respect to the consolidated financial statements of Disc Medicine, Inc. and the effectiveness of internal control over financial reporting of Disc Medicine, Inc. included in this Annual Report (Form 10-K) of Disc Medicine, Inc. for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Boston, Massachusetts

February 26, 2026

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer